All In Biotech

Drug Trial Radar · NCT00540449

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.

Last checked: Nov 20, 2026Latest source record: Mar 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 694 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

694

Actual

Start

May 2008

Primary completion

Feb 2010

Study completion Dec 2011

Sponsor

Sponsor type
Industry
First posted
Oct 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen consisting of emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF), in HIV-1 infected patients who have not yet taken any anti-HIV drugs. The following evaluations will be done: antiviral activity, immunologic changes, and viral geno-/phenotype evolution, relationship of Pharmacokinetics (PK) and PK/Pharmacodynamics, medical resource utilization and treatment adherence.

Conditions

  • HIV Infections
  • HIV-1
  • Human Immunodeficiency Virus Type 1

Interventions

  • TMC278Drug

    25 mg tablet once daily for 96 weeks

  • EfavirenzDrug

    600mg once daily for 96 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48Time frame: Week 48

Locations

92 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Beverly Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    Newport Beach, California

  • Site not named

    Sacramento, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Macon, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Baltimore, Maryland

  • Site not named

    Newark, New Jersey

  • Site not named

    Albany, New York

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Akron, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Columbia, South Carolina

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Córdoba, Argentina

  • Site not named

    Guernica, Argentina

  • Site not named

    Darlinghurst, Australia

  • Site not named

    Melbourne, Australia

  • Site not named

    Perth, Australia

  • Site not named

    Surry Hills, Australia

  • Site not named

    Innsbruck, Austria

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.